Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


RNAi: siRNA generation kits

Product Image
Product Description

Small Interfering RNA (siRNA)-mediated gene silencing is an exciting and valuable tool for studying gene function. However, most researchers are limited by their ability to test only a handful of chemically synthetic siRNAs due to high cost and lack of design guidance. Dicer siRNA Generation Kit allows cost-effective production of siRNAs targeted against entire gene sequences for efficient gene silencing. Harness the Natural Process. Most researchers purchase 3 to 8 chemically synthesized double-stranded siRNAs for each gene of interest to test whether they can get any strong gene silencing effect. This means synthesizing and processing 6 to 16 RNA oligonucleotides at a relatively high cost. The Dicer siRNA Generation Kits mimic the natural RNA interference process by using the recombinant human dicer enzyme to cleave in vitro transcribed dsRNA into a pool of 20 to 21-bp siRNAs.

Genlantis offers two different types of kits to generate siRNA: the original Dicer siRNA Generation Kits, and the more rapid Turbo Dicer siRNA Generation Kits. Additionally, multiple configurations and component kits of either the original or Turbo Dicer kits are offered to make these kits as convenient and cost effective as possible.

For the utmost in convenience and efficiency, Genlantis also offers one of the most widely-used and effective siRNA delivery reagents on the market, the GeneSilencer™ Transfection Reagent. The GeneSilencer reagent is provided as a prepackaged component of either Dicer siRNA generation kits, or it can be purchased separately in many different sizes and configurations. The GeneSilencer™ siRNA Transfection Reagent ensures efficient delivery of precious siRNA samples, no matter which method is used to produce these siRNAs.

Product RNAi: siRNA generation kits
Company Genlantis
Price Request a quote
More Information View company product page
Catalog Number Unspecified
Quantity Unspecified
Company Logo

Genlantis
Genlantis, Inc. 10190 Telesis Court San Diego, CA 92121 1-888-428-0558

Tel: 888-428-0558
Fax: 858-623-9494
Email: info@genlantis.com



Scientific News
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Shape Of Tumor May Affect Whether Cells Can Metastasize
Illinois researchers found that the shape of a tumor may play a role in how cancer cells become primed to spread.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."

SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!